Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

NCT05995535 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT05995535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05995535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Lead sponsor
University of Pennsylvania
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2024
Completion date
August 31, 2026
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

opiate withdrawal syndrome, opioid use